| Trial | Therapy | Allergen | No. of patients enrolled (in test group) | Allergen- specific IgE range(kUA/L) | Initial DBPCFC range (mg) | Final DBPCFC range (mg) | % desensitized |
|---|---|---|---|---|---|---|---|
| Leung (2003) | TNX-901 (450 | Peanut | 21 | 0.69-100 | 178 | 2803 | 24 |
| Sampson (2011) | Om alizum ab | Peanut | 9 | 7.1-323 | <5to 100 | 30-8000 | 11 |
| Savage (2012) | Om alizum ab | Peanut | 14 | 1.1-134 | 10-700 | 1830-10,000 | 29 |
| Nadeau (2011) | Om alizum ab +OIT | Milk | 11 | 41.6-342 | Not done | 8000 | 82 |
| Schneider (2013) | Om alizum ab +OIT | Peanut | 13 | 21-617 | ≤100 | 8000 | 92 |
| Begin (2014) | Om alizum ab + multi-OIT | Multiple (2 to 5) | 25 | 2-236 | ≤182 | 4000 per allergen (maintenance dose reached) | 100 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.